Finland: 3D Printing Patient-Specific Doses of Warfarin for Children

Finnish researchers reach further into the potential of 3D printed medications, outlining their findings in the recently published ‘Towards Printed Pediatric Medicines in Hospital Pharmacies: Comparison of 2D and 3D Printed Orodispersible Warfarin Films with Conventional Oral Powders in Unit Dose Sachets.’

Researchers continue to seek ways to prevent error in the dispensing of medications, along with offering more patient-specific, on-demand services in healthcare—with an even further sense of urgency to find better ways to treat children. In this study, the scientific team compared traditional techniques in preparing doses of warfarin—a commonly used blood thinner—at HUS Pharmacy in Finland with two new methods for dealing with pediatric dosage.

Experimenting with both semisolid extrusion 3D printing and inkjet printing, the researchers created samples of orodispersible films (ODFs) for a range of prescription strengths, at 0.1, 0.5, 1, and 2 mg.

Treating children can be challenging due to the obvious differences in size and weight, and the seriousness of an overdose. The dosages presented for the study are meant for infants aged 6 to 23 months and preschool children aged 2 to 6 years, with the ODFs composed of thin films that disintegrate quickly upon sticking to the tongue, with no water required. This is one benefit to making medication more enticing to kids, but aesthetic preferences are a considering too—especially for children—in terms of color, size, and taste.

“The different sizes for the EXT ODFs were designed to increase in volume in the same ratio as the dose escalation in order to enable the use of the same printing solution for manufacturing of all sizes. The final sizes of the IJP ODFs were designed to be equal to the sizes designed for the EXT,” stated the researchers.

Designed geometries for the ODFs

The team used a Biobots 1 printer to fabricate both placebo and drug-loaded ODFs, with films created on transparent sheets. The films were printed in three different batches, evaluated daily. For inkjet printing, the team used a PixDro LP50 piezoelectric printer with 128 nozzles, and a camera to monitor the jetted droplets.

“One printing run resulted in 32 printed films of a certain size that were allowed to dry in ambient conditions overnight and subsequently cut with a scalpel according to a template in order to obtain the final size,” stated the researchers.

Individual sachets were created, weighing 200 mg each, with three batches per dose size produced over three days. Drug concentration depended on the ‘wet weight’ of printed placebos and target doses. The samples and dosages were weighed after EXT printing, offering QA methods that could be used in a hospital setting.

“One discovered drawback with the used EXT printer was that it was difficult to attain the set pressure and even during printing of a single ODF the pressure would typically fluctuate. As pressure is one of the most important parameters to determine how much material is deposited per unit time, it may result in ODFs with fluctuating drug amount,” discussed the researchers. “Other factors to consider when using an EXT 3D printer is that the distance between the syringe tip and the build platform will have an impact on the amount of solution that is being deposited. Furthermore, the length of the tip and the amount of solution in the syringe was seen to influence the pressure required and the amount of solution being deposited. Consequently, at least all of these factors should be standardized or monitored to achieve ODFs with similar properties.”

IJP ODFs were also created in three steps using a modified, high concentration ink, with target doses created in a single layer.

“To achieve the target dose by printing a single layer, the dpi was calculated as described in the methods section,” explained the researchers. “No clogging of the nozzles was observed during printing with the described ink formulation, even though recrystallization during printing of high concentration inks containing solvents that are easily evaporated may be of concern for IJP.”

Manufacturing times for EXT ODFs and IJP ODFs. The manufacturing time includes the actual printing time, not premanufacturing steps nor drying times of films. For inkjet printing 51 ± 9 nozzles were used for target doses 0.1, 0.5, and 1 mg and 45 ± 7 nozzles for a target dose of 2 mg.

All the prepared ODF samples possessed suitable mechanical properties and were ‘superior’ in comparison to traditionally made counterparts, in terms of uniformity, leaving the research team confident about the possibility of printing them in a hospital, fabricating patient-specific doses.

(A) EXT drug-loaded ODF imprinted with a QR code containing information about the dosage form and (B) the same EXT ODF rolled up to visualize the flexibility of the film. (C) IJP drug-loaded ODF with a printed QR code and (D) the flexible ODF is subsequently coiled up for illustrative purposes.

“This study, among other recent studies in the field, have shown the feasibility and potential of using printing techniques for manufacturing of flexible doses, contributing to safer and improved treatments for various patient groups in the future,” concluded the researchers. “In order to produce personalized on-demand dosage forms for children in a hospital pharmacy setting, special attention should be paid to the safety of used excipients, implementation of suitable non-destructive and fast quality assurance methods. Furthermore, the possibility to use disposable parts instead of time-consuming cleaning procedures and short turnaround time for the complete manufacturing process including printing solution preparation and drying time of final dosage form should be ensured in order to successfully implement printing methods as a part of the manufacturing techniques used in a hospital pharmacy.”

Stability of the manufactured dosage forms with a target dose of 2 mg at time points 1, 7, 14, 21, and 28 days. The gray columns represent the target dose of 2 mg. Data shown as average ± SD, n = 10.

As 3D printing continues to make countless impacts in the medical field, medication is definitely an area where there will be long-lasting changes, from creating accelerated doses to DIY drugs and medication dispensers.

What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.

Pictures of the prepared dosage forms: (A) EXT ODFs; (B) IJP ODFs; (C) oral powder; and (D) OPS.

[Source / Images: ‘Towards Printed Pediatric Medicines in Hospital Pharmacies: Comparison of 2D and 3D Printed Orodispersible Warfarin Films with Conventional Oral Powders in Unit Dose Sachets’]

 

The post Finland: 3D Printing Patient-Specific Doses of Warfarin for Children appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.

Added Scientific Used Xaar Printhead in Pilot Project for 3D Printing Personalized Pharmaceuticals

Cambridge-based company Xaar may have had its start in developing piezoelectric, drop-on-demand industrial printheads, but transitioned to the 3D printing world back in 2014 when it helped develop the high speed sintering (HSS) FACTUM 3D printer. Xaar is also a leading developer of digital inkjet printing technology, and is currently helping research organization Added Scientific, headquartered in Nottingham, as it works to determine how suitable inkjet printing is in fabricating personalized pharmaceuticals.

Added Scientific, a spinoff company from the University of Nottingham, is using Xaar’s 1201 printhead to bring personalized medicine, with dosages tailored to individual people on an industrial scale, just one step closer to reality.

Craig Sturgess, Research Manager for Added Scientific, said, “Inkjet printing offers the ability to digitally control the printing with its precision placement of tiny droplets a few picolitres in size and the capability to place multiple materials to create complex multi-functional objects in 2D & 3D.

The project was initiated by Added Scientific with its collaborating partners Xaar and global pharmaceutical company AstraZeneca and funded under the UK government’s Industrial Strategy Challenge Fund’s Medicines Manufacturing Challenge, with additional support from Innovate UK. They’re building on research previously conducted at the university regarding the development of excipients: everything but the active pharmaceutical ingredient (API). This pilot project is looking at the long-term suitability and scalability of using inkjet printing to dispense APIs.

“Trial research carried out previously has shown that inkjet offers a real potential for printed medicines. This project was designed to answer questions pharmaceutical companies have around the suitability of inkjet printing in dispensing APIs at a scale that made both manufacturing and economic sense,” Sturgess continued.

The project partners used the Xaar 1201 printhead with one of the university’s formulations to evaluate its impact on the API, in addition to how well it can operate under Good Manufacturing Practice (GMP) conditions. GMP is the de facto standard for manufacturing in the pharmaceutical industry. They also studied if the formulation had an effect on the life of the printhead, and rounded out their experimental trials by evaluating AstraZeneca’s data from conventional tablet manufacturing against inkjet printing process times.

Xaar’s 1201 printhead

“The Xaar 1201 is ideal for a wide range of industrial applications including Advanced Manufacturing due to its ability to print fluids with a range of viscosities, reactivity and conductivity. This pilot project has demonstrated the Xaar 1201’s versatility for pharmaceuticals and how inkjet printing is proving itself to have the potential to drive innovation as well as efficiencies in many areas of 21 st century life,” stated Mike Seal, Business Development Manager, Advanced Manufacturing, at Xaar.

The results from the team’s project showed significant time saved in unit process times from inkjet printing in comparison to conventional manufacturing methods. Production trials consisted of 1,000 dosage forms printed in batches of 100, and no issues or interaction with the API occurred in Xaar’s 1201 printhead; additionally, there was no impact on the life of the printhead itself.

“These are exciting times. Our project has clearly shown that printing personalised medicines – with all their advantages of dose and design freedom – is no longer just a theory, but a scalable and economic reality for pharmaceutical companies and we look forward to extended trials to confirm these findings,” Sturgess concluded.

Added Scientific and its project partners are certainly not the first to investigate the idea of using 3D printing to fabricate personalized medication, and I doubt they will be the last. However, inkjet printing is not typically used to make 3D printed medication, so it will be interesting to see what the team’s next steps will be.

Discuss this story and other 3D printing topics at 3DPrintBoard.com or share your thoughts in the Facebook comments below.

[Images: Xaar]